Abstract 1651P
Background
The exact origin and associated prognosis of periampullary adenocarcinoma might be challenging to determine, especially in bulky tumours, due to the destruction of normal periampullary anatomy and the extension of the tumour beyond a single periampullary structure. Periampullary carcinomas are typically divided into pancreatobiliary and intestinal types according to histological differentiation. The aim of this study was to determine the prognostic value of this histological differentiation by comparing various clinic-pathological prognostic factors and surgical outcome in periampullary carcinoma cases that underwent pancreaticoduodenectomy.
Methods
From May 2018 to April 2021, 60 consecutive cases of periampullary carcinoma who underwent pancreaticoduodenectomy were included in this study. Cases were divided into two groups: pancreatobiliary and intestinal types. Various clinical and histopathological prognostic variables were analysed, and the association of these variables with pancreatobiliary and intestinal variants of periampullary carcinoma was determined using Chi-square and Fischer’s exact tests.
Results
20 cases were included in the pancreatobiliary group, and 40 cases were included in the intestinal group. These groups were comparable in terms of age, sex, nutritional status, and bilirubin levels. Pancreatobiliary type was more frequently associated with nodal disease (p<0.01), lymphovascular invasion (p<0.01) and perineural invasion (p=0.018). Post-operative morbidity was significantly higher in the pancreatobiliary group (p=0.043). Table: 1651P
S.No. | Variable | Periampullary Carcinoma | x2 | p-value | ||
Pancreatobiliary Type | Intestinal Type | |||||
1 | Age (years) | <60 | 15 | 32 | 0.196 | 0.658 |
>60 | 5 | 8 | ||||
2 | Sex | Male | 12 | 19 | 0.834 | 0.361 |
Female | 8 | 21 | ||||
3 | Comorbidity | Yes | 6 | 16 | 0.574 | 0.449 |
No | 24 | 24 | ||||
4 | Bilirubin (mg/dl) | <5 | 8 | 8 | 2.73 | 0.099 |
>5 | 12 | 32 | ||||
5 | Albumin (g/dl) | < 3 | 8 | 11 | 0.96 | 0.326 |
> 3 | 12 | 29 | ||||
6 | Pancreas Texture | Firm | 10 | 21 | 0.03 | 0.855 |
Soft | 10 | 19 | ||||
7 | MPD | <3mm | 6 | 5 | 2.73 | 0.99 |
>3mm | 14 | 35 | ||||
8 | Tumor size | >2cm | 8 | 21 | 0.834 | 0.361 |
<2cm | 12 | 19 | ||||
9 | Nodal status | Positive | 12 | 10 | 7.03 | 0.008 |
Negative | 8 | 30 | ||||
10 | Lymphovascular Invasion | Present | 12 | 9 | 8.24 | 0.004 |
Absent | 8 | 31 | ||||
11 | Perineural Invasion | Present | 7 | 4 | 5.57 | 0.018 |
Absent | 13 | 36 | ||||
12 | Grade | 1 | 10 | 15 | 0.857 | 0.355 |
2/3 | 10 | 25 | ||||
13 | Post-operative Morbidity | Yes | 11 | 08 | 4.10 | 0.043 |
No | 9 | 32 |
Conclusions
After pancreaticoduodenectomy, periampullary cancer of the pancreatobiliary type is linked to worse post-operative outcome and unfavourable histopathological prognostic markers. Therefore, after surgery, these cases should follow management algorithms with aggressive adjuvant therapy protocols.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22